185 related articles for article (PubMed ID: 26258989)
1. Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma.
Ajona D; Pajares MJ; Chiara MD; Rodrigo JP; Jantus-Lewintre E; Camps C; Suarez C; Bagán JV; Montuenga LM; Pio R
Oral Dis; 2015 Oct; 21(7):899-904. PubMed ID: 26258989
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and immunohistochemical evaluation of oral and oropharyngeal squamous cell carcinoma in Chilean population.
Rivera C; González-Arriagada WA; Loyola-Brambilla M; de Almeida OP; Coletta RD; Venegas B
Int J Clin Exp Pathol; 2014; 7(9):5968-77. PubMed ID: 25337241
[TBL] [Abstract][Full Text] [Related]
3. Salivary Tumour Necrosis Factor-α as a Biomarker in Oral Leukoplakia and Oral Squamous Cell Carcinoma.
G D; Nandan SRK; Kulkarni PG
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2087-2093. PubMed ID: 31350970
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.
Ajona D; Razquin C; Pastor MD; Pajares MJ; Garcia J; Cardenal F; Fleischhacker M; Lozano MD; Zulueta JJ; Schmidt B; Nadal E; Paz-Ares L; Montuenga LM; Pio R
PLoS One; 2015; 10(3):e0119878. PubMed ID: 25799154
[TBL] [Abstract][Full Text] [Related]
5. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of saliva and plasma cytokine biomarkers in patients with oral squamous cell carcinoma.
Lee LT; Wong YK; Hsiao HY; Wang YW; Chan MY; Chang KW
Int J Oral Maxillofac Surg; 2018 Jun; 47(6):699-707. PubMed ID: 29174861
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of salivary endothelin-1 levels in oral squamous cell carcinoma and oral leukoplakia.
Hoffmann RR; Yurgel LS; Campos MM
Regul Pept; 2011 Jan; 166(1-3):55-8. PubMed ID: 20727373
[TBL] [Abstract][Full Text] [Related]
8. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.
Ajona D; Pajares MJ; Corrales L; Perez-Gracia JL; Agorreta J; Lozano MD; Torre W; Massion PP; de-Torres JP; Jantus-Lewintre E; Camps C; Zulueta JJ; Montuenga LM; Pio R
J Natl Cancer Inst; 2013 Sep; 105(18):1385-93. PubMed ID: 23940286
[TBL] [Abstract][Full Text] [Related]
9. Significance of Expression of Complement C4d in Esophageal Squamous Cell Carcinoma.
Kikuchi M; Nakajima M; Muroi H; Takahashi M; Itoh J; Yamaguchi S; Sasaki K; Kato H
Anticancer Res; 2016 Sep; 36(9):4553-7. PubMed ID: 27630295
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Prion protein and its clinical significance in oral squamous cells carcinoma and oral leukoplakia].
Zhang J; Zeng Y; Zheng J; Xu J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2013 Dec; 48(12):752-4. PubMed ID: 24495728
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral submucous fibrosis.
Varun BR; Ranganathan K; Rao UK; Joshua E
J Investig Clin Dent; 2014 Aug; 5(3):214-9. PubMed ID: 23776093
[TBL] [Abstract][Full Text] [Related]
12. Salivary metabolite signatures of oral cancer and leukoplakia.
Wei J; Xie G; Zhou Z; Shi P; Qiu Y; Zheng X; Chen T; Su M; Zhao A; Jia W
Int J Cancer; 2011 Nov; 129(9):2207-17. PubMed ID: 21190195
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study.
Babiuch K; Bednarczyk A; Gawlik K; Pawlica-Gosiewska D; Kęsek B; Darczuk D; Stępień P; Chomyszyn-Gajewska M; Kaczmarzyk T
Acta Odontol Scand; 2019 Aug; 77(6):408-418. PubMed ID: 30857448
[No Abstract] [Full Text] [Related]
14. Salivary mRNA markers having the potential to detect oral squamous cell carcinoma segregated from oral leukoplakia with dysplasia.
Michailidou E; Tzimagiorgis G; Chatzopoulou F; Vahtsevanos K; Antoniadis K; Kouidou S; Markopoulos A; Antoniades D
Cancer Epidemiol; 2016 Aug; 43():112-8. PubMed ID: 27263493
[TBL] [Abstract][Full Text] [Related]
15. Analysis of tumor marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study.
Balan JJ; Rao RS; Premalatha BR; Patil S
J Contemp Dent Pract; 2012 Sep; 13(5):671-5. PubMed ID: 23250173
[TBL] [Abstract][Full Text] [Related]
16. Expression of Fas and Fas-ligand and analysis of argyrophilic nucleolar organizer regions in squamous cell carcinoma: relationships with tumor stage and grade, and apoptosis.
Guler N; Uckan S; Celik I; Oznurlu Y; Uckan D
Int J Oral Maxillofac Surg; 2005 Dec; 34(8):900-6. PubMed ID: 15907374
[TBL] [Abstract][Full Text] [Related]
17. Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma.
Sridharan G; Ramani P; Patankar S
J Cancer Res Ther; 2017; 13(3):556-561. PubMed ID: 28862226
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma and salivary cortisol levels in patients with oral cancer and their association with clinical stage.
Bernabé DG; Tamae AC; Miyahara GI; Sundefeld ML; Oliveira SP; Biasoli ÉR
J Clin Pathol; 2012 Oct; 65(10):934-9. PubMed ID: 22734006
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of salivary and serum lipid peroxidation, and glutathione in oral leukoplakia and oral squamous cell carcinoma.
Metgud R; Bajaj S
J Oral Sci; 2014 Jun; 56(2):135-42. PubMed ID: 24930750
[TBL] [Abstract][Full Text] [Related]
20. Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients.
Li SX; Yang YQ; Jin LJ; Cai ZG; Sun Z
Cancer Biomark; 2016; 17(4):377-382. PubMed ID: 27662323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
